Revenue Performance - Revenue for Q3 2025 was $6.8 million, a 78% increase sequentially and a 76% increase year-over-year compared to Q3 2024's $3.9 million[5] - Total revenue for the three months ended September 30, 2025, was $6,783 million, a significant increase from $3,860 million in the same period of 2024, representing a growth of 76.5%[21] - Product revenue reached $2,195 million for the three months ended September 30, 2025, compared to $1,958 million in 2024, marking an increase of 12.1%[21] - Service revenue surged to $4,588 million for the three months ended September 30, 2025, up from $1,902 million in 2024, reflecting a growth of 141.5%[21] Profitability and Loss - Gross profit for Q3 2025 was $3.9 million, reflecting an increase from $2.3 million in Q3 2024, while gross margin declined to 58% from 60% year-over-year[5] - Gross profit for the three months ended September 30, 2025, was $3,937 million, compared to $2,334 million in 2024, indicating an increase of 68.8%[21] - The operating loss for Q3 2025 increased to $4.7 million from $2.6 million in Q3 2024[5] - Operating loss for the three months ended September 30, 2025, was $(4,734) million, widening from $(2,645) million in the same period of 2024[21] - Net loss for the three months ended September 30, 2025, was $(5,400) million, compared to $(2,616) million in 2024, representing an increase in loss of 106.8%[21] - Net loss per share (basic and diluted) for the three months ended September 30, 2025, was $(0.49), compared to $(0.40) in 2024[21] Expenses and Financial Position - Operating expenses for Q3 2025 were $8.7 million, a 74% increase from $5.0 million in Q3 2024, primarily due to increased headcount and depreciation expenses related to the SCN acquisition[5] - Total operating expenses for the three months ended September 30, 2025, were $8,671 million, up from $4,979 million in 2024, reflecting a rise of 74.5%[21] - Cash and cash equivalents decreased to $3.1 million as of September 30, 2025, down from $6.3 million at the end of 2024[5] - Stockholders' equity was $2.5 million as of September 30, 2025, compared to $8.0 million at the end of 2024[5] Strategic Initiatives - The acquisition of The Sleep Center of Nevada contributed $2.2 million in diagnostic sleep testing revenue and $1.3 million in treatment center revenue during Q3 2025[5] - Vivos plans to expand its model into additional major markets beyond Las Vegas through acquisitions or contractual alliances with sleep medical practices[3] - The company is actively working to add new sleep optimization teams in 2026 to reduce cash burn and create potential for profitable operations[4] - Vivos has entered into a management agreement with MISleep Solutions LLC to provide its treatments and services in Auburn Hills, Michigan, with patient services expected to begin in early December 2025[7] Shareholder Information - The weighted average number of shares outstanding (basic and diluted) increased to 10,963,590 for the three months ended September 30, 2025, from 6,615,320 in 2024[21] - Non-operating income (expense) included other expense of $(679) million for the three months ended September 30, 2025, compared to $(18) million in 2024[21]

Core Insights - Vivos Therapeutics reported a 78% sequential revenue growth in Q3 2025, driven by the first full quarter of operations from the Sleep Center of Nevada acquisition, with a year-over-year revenue increase of 76% [2][4] - The strategic pivot from a dental distribution model to direct affiliations and acquisitions of medical sleep practices is yielding positive results, as evidenced by the revenue contributions from the Sleep Center of Nevada [2][4] - The company is optimistic about growth potential in the Las Vegas area and plans to expand its model into other major markets [2][6] Financial Performance - Q3 2025 revenue reached $6.8 million, up from $3.9 million in Q3 2024, while revenue for the nine months ended September 30, 2025, was $13.6 million compared to $11.3 million in the same period of 2024 [4][23] - Gross profit for Q3 2025 was $3.9 million, reflecting an increase from $2.3 million in Q3 2024, with gross margins at 58% compared to 60% in the previous year [4][11] - Operating expenses rose to $8.7 million in Q3 2025, a 74% increase from $5.0 million in Q3 2024, primarily due to increased headcount and expenses related to the SCN acquisition [11][23] Strategic Initiatives - The acquisition of the Sleep Center of Nevada has introduced new revenue streams, contributing $2.2 million in diagnostic sleep testing revenue and $1.3 million in treatment center revenue during Q3 2025 [4][23] - Vivos is implementing an updated sleep practice affiliation model to collaborate with sleep centers that prefer not to be acquired, allowing them to offer Vivos' diagnostic and treatment options [5][6] - The company is actively seeking similar management agreements in other major markets to expand its reach and service offerings [6] Market Outlook - Vivos anticipates significant local market growth potential in Las Vegas, with patient bookings extending into February 2026 as they work to enhance operations and capacity [2][4] - The company plans to continue adding new sleep optimization teams in 2026, which is expected to reduce cash burn and pave the way for profitable operations [3][11]

Revenue Performance - Total revenue for Q3 2025 was $6,783,000, a 76% increase from $3,860,000 in Q3 2024[18] - Product revenue increased to $2,195,000 in Q3 2025, up 12% from $1,958,000 in Q3 2024[18] - Service revenue surged to $4,588,000 in Q3 2025, compared to $1,902,000 in Q3 2024, representing a 142% increase[18] - For the three months ended September 30, 2025, the company incurred a net loss of $5.4 million, compared to a net loss of $2.6 million for the same period in 2024[149] - Pro forma net revenue for the three months ended September 30, 2025, was $6.8 million, compared to $5.8 million for the same period in 2024[88] Financial Losses - Operating loss for Q3 2025 was $(4,734,000), compared to $(2,645,000) in Q3 2024, indicating a worsening of 79%[18] - Net loss for Q3 2025 was $(5,400,000), compared to $(2,616,000) in Q3 2024, representing a 106% increase in losses[18] - For the nine months ended September 30, 2025, the net loss was $14.276 million, compared to a net loss of $8.309 million for the same period in 2024, representing a 72% increase in losses[24] Assets and Liabilities - Total assets as of September 30, 2025, were $25,644,000, significantly up from $15,284,000 as of December 31, 2024[15] - Total liabilities increased to $23,112,000 as of September 30, 2025, compared to $7,330,000 at the end of 2024[15] - Stockholders' equity decreased to $2,532,000 as of September 30, 2025, down from $7,954,000 as of December 31, 2024[15] Cash Flow and Financing - Net cash used in operating activities was $11.451 million for the nine months ended September 30, 2025, compared to $9.751 million for the same period in 2024, indicating a 17% increase in cash outflow[24] - The company reported net cash provided by financing activities of $14.223 million for the nine months ended September 30, 2025, compared to $14.822 million for the same period in 2024, showing a slight decrease of 4%[24] - Cash and cash equivalents at the end of the year were $3.087 million, down from $6.311 million at the end of the previous year, reflecting a decrease of 51%[24] Strategic Acquisitions and Business Model - The company acquired all operating assets of The Sleep Center of Nevada for a total consideration of $6.0 million in cash and $1.5 million in common stock, marking a strategic expansion into sleep disorder treatment[29] - The company is exploring additional acquisitions and collaborations with medical sleep practices to expand its business model and revenue streams[37] - The company has shifted its focus to direct patient services, including home sleep screenings and telemedicine, under its new business strategy[32] Revenue Recognition and Customer Contracts - Revenue recognition follows ASC Topic 606, with legacy VIP enrollment revenue expected to continue through 2026[44] - Estimated customer life for VIP contracts ranges from 14 to 27 months, impacting revenue recognition timing[48] - Revenue from appliance sales is recognized upon transfer of control to the VIP, with the company acting as the principal in the transaction[59] Market and Operational Challenges - The Federal Reserve's elevated interest rates pose a risk to the company's revenue, earnings, and access to capital[207] - Changes in U.S. trade policy and tariffs may materially impact the company's sourcing strategy and competitiveness of contract manufacturers[205] - Ongoing geopolitical tensions, including the war in Ukraine and Middle East hostilities, could adversely affect demand for the company's products and capital market stability[209] Compliance and Regulatory Matters - The company received a notice from Nasdaq regarding non-compliance with the $2,500,000 minimum stockholders' equity requirement as of March 31, 2024[211] - Following a $7.5 million equity private placement, the company reported compliance with the equity requirement and received continued listing approval from Nasdaq[211] - The company is exploring additional equity capital financings to maintain compliance with Nasdaq's equity requirement[212]

Core Viewpoint - Vivos Therapeutics, Inc. is set to release its third quarter 2025 financial results and will discuss strategic collaborations that may impact revenue growth and cash burn during a conference call scheduled for November 19, 2025 [1][2]. Company Overview - Vivos Therapeutics, Inc. specializes in medical devices and healthcare services for sleep-related breathing disorders, particularly obstructive sleep apnea (OSA) [5]. - The company has developed proprietary treatments and diagnostic procedures, with its devices cleared by the FDA for various severity levels of OSA in both adults and children [5]. - Vivos' Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first for moderate to severe OSA in children [5]. Market Context - OSA affects over 1 billion people globally, with 90% undiagnosed, linking it to serious chronic health conditions [6]. - Traditional treatments like CPAP often fail to address the root causes of OSA, indicating a need for innovative solutions [6]. Strategic Initiatives - Vivos aims to enhance its market position through technology, education, and collaborations with sleep healthcare providers to better address OSA patients' needs [7]. - The company promotes The Vivos Method, a proprietary, clinically effective, nonsurgical, noninvasive, and nonpharmaceutical solution for OSA [8].

Company Overview - Vivos Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders via live webcast, emphasizing the shift towards virtual meetings for improved accessibility and attendance [1][3]. Leadership and Structure - Kirk Huntsman serves as the Chief Executive Officer and Chairman of the Board of Directors, with Brad Amman acting as Chief Financial Officer and Secretary of the meeting [2]. Voting and Participation - Stockholders of record as of September 8, 2025, are eligible to vote either by proxy or virtually during the meeting, allowing for greater participation [3]. - Shareholders who have already submitted a proxy and do not wish to change their vote are not required to vote again, streamlining the voting process [4].

Core Insights - Vivos Therapeutics has released clinical data indicating that its FDA-cleared Daytime-Nighttime Appliance (DNA) provides significant relief for children suffering from ADHD and obstructive sleep apnea (OSA) [1][6] Company Overview - Vivos Therapeutics, Inc. specializes in developing and commercializing treatments for sleep-related breathing disorders, particularly OSA [1][9] - The DNA appliance is the only FDA 510(k) cleared non-surgical, non-pharmaceutical treatment for moderate to severe pediatric OSA in children aged 6-17 [2][10] Market Context - The diagnosed rates of ADHD in the U.S. have increased from approximately 2-3% in the 1980s to over 11% by 2022, while the prevalence of OSA in preschool children rose from 3-9% before 2014 to 13-20% by 2022 [3][4] - There is a strong correlation between pediatric OSA and ADHD symptoms, with up to 95% of pediatric OSA patients exhibiting attention deficits [4][6] Clinical Data Findings - In a recent dataset, children treated with the Vivos DNA appliance reported a 50% decrease in the Pediatric Sleep Questionnaire scores and a 58% decrease in symptoms related to sleep-disordered breathing and ADHD [6][7] - The clinical trial included 55 patients, with 48 completing the study, showing significant improvements in airway volume (+40%) and a reduction in OSA severity by 51.4% [7][8] Treatment Implications - The improvements in OSA and ADHD symptoms may enhance children's academic performance and overall quality of life, with most benefits observed within the first six months of treatment [8]

Core Insights - Several small- and mid-cap biotech and medical stocks experienced significant after-hours trading activity on September 26, driven by clinical updates, investor presentations, and strategic announcements. Company Summaries - **Enanta Pharmaceuticals Inc. (ENTA)**: The stock surged 20% in after-hours trading to $9.48 after closing at $7.90, following the announcement of upcoming topline results from its Phase 2b study on zelicapavir for RSV treatment in high-risk adults [2][3]. - **Acumen Pharmaceuticals Inc. (ABOS)**: Shares rebounded 12.67% to $1.60 after closing at $1.42, driven by renewed interest in its Alzheimer's pipeline, particularly the Phase 2 candidate Sabirnetug (ACU193) [4]. - **Delcath Systems Inc. (DCTH)**: The stock gained 6.00% in after-hours trading to $11.39 after closing at $10.74, following renewed investor interest in its CHOPIN Phase 2 trial data presentation scheduled for ESMO 2025 Congress [5][6]. - **Vivos Therapeutics Inc. (VVOS)**: The stock climbed 4.81% to $3.27 after closing at $3.12, likely due to renewed interest following recent positive clinical trial results for its pediatric OSA treatment [7][8]. - **Xilio Therapeutics (XLO)**: Shares rose 4.28% to $0.83 after closing at $0.7959, driven by enthusiasm surrounding the initiation of a Phase 2 trial for its tumor-activated IL-12 candidate, which also triggered a $17.5 million payment from Gilead [9][10]. - **Nyxoah SA (NYXH)**: The stock increased 3.77% to $4.68 after closing at $4.51, supported by optimism regarding its international expansion and a recent patent infringement lawsuit against Inspire Medical Systems [11].

Core Insights - Vivos Therapeutics has published peer-reviewed data confirming the safety and efficacy of its Vivos DNA appliance in treating pediatric obstructive sleep apnea (OSA) [1][2][4] - The study highlights a significant milestone in addressing pediatric OSA, a condition affecting up to 20.4% of U.S. children, with many remaining undiagnosed [3][10] Group 1: Clinical Trial Results - The multicenter clinical trial results published in the European Journal of Pediatrics show that 77% of participants experienced at least a 50% reduction in OSA severity [7] - Among children with severe OSA, 93% achieved a 50% reduction in severity, and 17% of patients experienced complete resolution of their OSA [7] - The average airway volume increased by 67.8%, and Pediatric Sleep Questionnaire symptom scores decreased by 31%, indicating statistically significant improvement [7] Group 2: Treatment Alternatives - The Vivos DNA appliance is positioned as a non-surgical alternative to the current standard of care, which is adenotonsillectomy (AT) surgery, effective in only 20-40% of pediatric cases [3][4] - Vivos also offers Vivos Guides, which support proper craniofacial growth and have shown to alleviate symptoms associated with underdeveloped jaw growth, including ADHD behaviors and bedwetting [6][15] - Clinical data indicates that Vivos Guides can virtually eliminate bedwetting in children, with 50% seeing results within two weeks and 97.4% resolving within 60 days [6] Group 3: Industry Context - OSA affects over 1 billion people globally, with 90% undiagnosed, linking it to serious chronic health conditions [10] - Vivos Therapeutics aims to address the complex needs of OSA patients through innovative technology and collaborations with healthcare providers [11] - The company’s Complete Airway Repositioning and Expansion (C.A.R.E.) devices are the only FDA-cleared technology for treating severe OSA in adults and moderate to severe OSA in children [9]

[Q2 2025 Earnings Release Highlights](index=1&type=section&id=Q2%202025%20Earnings%20Release%20Highlights) Vivos Therapeutics' Q2 2025 highlights include a strategic pivot in its sales model through the SCN acquisition and a decline in financial performance due to this transition [Business and Strategic Highlights](index=1&type=section&id=Business%20and%20Strategic%20Highlights) The second quarter of 2025 was marked by Vivos Therapeutics' strategic pivot in its sales, marketing, and distribution model, highlighted by the acquisition of The Sleep Center of Nevada (SCN) - Vivos completed the key acquisition of The Sleep Center of Nevada (SCN), the largest operator of medical sleep centers in Nevada, marking a pivot in its core sales, marketing, and distribution model[3](index=3&type=chunk) - The new model allows Vivos to capture both OSA diagnostic and treatment revenue through more direct relationships with patients[3](index=3&type=chunk) - SCN generated approximately **$500,000** of diagnostic sleep testing services revenue over just twenty days from the June 10 closing to the end of the quarter[3](index=3&type=chunk) - Patient demand at SCN locations adapted to the Vivos model so far continues to exceed current capacity, with appointments booked out for weeks and less than **40% of patients** currently being served, validating the new model[3](index=3&type=chunk) [Financial Performance Summary](index=1&type=section&id=Financial%20Performance%20Summary) Vivos Therapeutics reported a decline in Q2 2025 revenue and gross profit, primarily due to its strategic pivot in sales and distribution model, leading to a larger operating loss Q2 2025 and YTD June 30, 2025 Key Financials | Metric | Q2 2025 (Millions USD) | Q2 2024 (Millions USD) | Change (YoY) | YTD 2025 (Millions USD) | YTD 2024 (Millions USD) | Change (YoY) | | :----- | :--------------------- | :--------------------- | :----------- | :---------------------- | :---------------------- | :----------- | | Revenue | $3.8 | $4.1 | -7.3% | $6.8 | $7.5 | -9.3% | | Gross Profit | $2.1 | $2.7 | -22.2% | $3.6 | $4.6 | -21.7% | | Gross Margin | 55% | 65% | -10 pp | 53% | 61% | -8 pp | | Operating Expenses | $7.0 | $4.6 | +52.2% | $12.4 | $10.3 | +20.4% | | Operating Loss | $(4.9) | $(1.9) | +157.9% | $(8.8) | $(5.7) | +54.4% | Cash and Stockholders' Equity | Metric | June 30, 2025 (Millions USD) | Dec 31, 2024 (Millions USD) | Change | | :----- | :--------------------------- | :-------------------------- | :----- | | Cash and Cash Equivalents | $4.4 | $6.2 | -29.0% | | Stockholders' Equity | $4.6 | $8.0 | -42.5% | - The decline in revenue and gross profit was expected and attributed to the ongoing pivot in Vivos' sales, marketing, and distribution model, focusing on sleep center provider-based alliances and acquisitions[4](index=4&type=chunk)[7](index=7&type=chunk) - The increase in operating expenses was due to higher general and administrative costs, including professional fees related to equity and debt financings for the SCN acquisition and integration, much of which is expected to be non-recurring[7](index=7&type=chunk) [Strategic Business Model Transformation](index=1&type=section&id=Strategic%20Business%20Model%20Transformation) Vivos Therapeutics is strategically transforming its business model through the acquisition of SCN and the development of a new OSA provider management model [Acquisition of The Sleep Center of Nevada (SCN)](index=1&type=section&id=Acquisition%20of%20The%20Sleep%20Center%20of%20Nevada%20(SCN)) Vivos completed the acquisition of The Sleep Center of Nevada (SCN) on June 10, 2025, as a cornerstone of its strategic shift, aiming to directly engage patients for OSA diagnosis and treatment - Vivos acquired The Sleep Center of Nevada (SCN) on June 10, 2025, pivoting its sales, marketing, and distribution model[3](index=3&type=chunk)[4](index=4&type=chunk) - The acquisition enables Vivos to capture both OSA diagnostic and treatment revenue through direct patient relationships, moving away from a model solely reliant on dentists[3](index=3&type=chunk) - SCN generated approximately **$500,000** in diagnostic sleep testing services revenue in the 20 days following the acquisition[3](index=3&type=chunk) - Patient demand at SCN locations, adapted to the Vivos model, currently exceeds capacity, with appointments booked for weeks and less than **40% of patients** being served, validating the new model[3](index=3&type=chunk) - Vivos plans to scale this model in the future through additional sleep center alliances or acquisitions[3](index=3&type=chunk) [Updated OSA Provider Management Model](index=2&type=section&id=Updated%20OSA%20Provider%20Management%20Model) Vivos is developing a new sleep practice management model, exemplified by its agreement with MISleep Solutions LLC, to offer its full suite of OSA treatments and services through equity stakes in management companies - Vivos is developing an updated sleep practice management model for medical practices not interested in being purchased but willing to offer Vivos' OSA diagnostic and treatment options[5](index=5&type=chunk) - On July 14, 2025, Vivos entered its first management agreement with MISleep Solutions LLC in Auburn Hills, Michigan, to provide its full suite of Vivos treatments and services[6](index=6&type=chunk) - Vivos holds a **supermajority equity stake** in the management services company under this model, with sleep doctors having minority ownership[6](index=6&type=chunk) - Facilities for these operations are being remodeled, with an estimated opening in October 2025, and Vivos is exploring similar arrangements in other states[6](index=6&type=chunk) [Detailed Financial Results](index=5&type=section&id=Detailed%20Financial%20Results) Detailed financial results for Q2 2025 show decreased revenue and increased operating losses, alongside significant balance sheet changes reflecting recent acquisitions and debt [Condensed Consolidated Statements of Operations](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) For Q2 2025, Vivos Therapeutics experienced a decrease in total revenue and gross profit compared to Q2 2024, primarily driven by lower service revenue, leading to a substantial rise in operating and net loss Condensed Consolidated Statements of Operations (Q2 2025 vs Q2 2024) | Metric (Thousands USD) | Q2 2025 | Q2 2024 | Change | | :-------------------- | :------ | :------ | :----- | | Product revenue | $1,885 | $1,975 | -4.6% | | Service revenue | $1,935 | $2,079 | -6.9% | | **Total revenue** | **$3,820** | **$4,054** | **-5.8%** | | Cost of sales | $1,710 | $1,403 | +21.9% | | **Gross profit** | **$2,110** | **$2,651** | **-20.4%** | | General and administrative | $6,409 | $4,122 | +55.5% | | Sales and marketing | $260 | $320 | -18.8% | | Depreciation and amortization | $306 | $145 | +111.0% | | **Total operating expenses** | **$6,975** | **$4,587** | **+52.1%** | | **Operating loss** | **$(4,865)** | **$(1,936)** | **+151.3%** | | **Net loss** | **$(5,013)** | **$(1,930)** | **+159.7%** | | Net loss per share (basic and diluted) | $(0.55) | $(0.60) | -8.3% | | Weighted average shares outstanding | 9,087,202 | 3,228,363 | +181.5% | Condensed Consolidated Statements of Operations (Six Months Ended June 30, 2025 vs 2024) | Metric (Thousands USD) | YTD 2025 | YTD 2024 | Change | | :-------------------- | :------- | :------- | :----- | | Product revenue | $3,698 | $3,650 | +1.3% | | Service revenue | $3,137 | $3,823 | -17.9% | | **Total revenue** | **$6,835** | **$7,473** | **-8.5%** | | Cost of sales | $3,219 | $2,885 | +11.6% | | **Gross profit** | **$3,616** | **$4,588** | **-21.2%** | | General and administrative | $11,298 | $9,043 | +24.9% | | Sales and marketing | $615 | $973 | -36.8% | | Depreciation and amortization | $483 | $291 | +66.0% | | **Total operating expenses** | **$12,396** | **$10,307** | **+20.3%** | | **Operating loss** | **$(8,780)** | **$(5,719)** | **+53.5%** | | **Net loss** | **$(8,877)** | **$(5,692)** | **+55.9%** | | Net loss per share (basic and diluted) | $(1.00) | $(2.06) | -51.4% | | Weighted average shares outstanding | 8,842,604 | 2,768,934 | +219.3% | [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2025, Vivos Therapeutics reported a significant increase in total assets, primarily driven by goodwill, property and equipment, and intangible assets, reflecting recent acquisitions Condensed Consolidated Balance Sheets (June 30, 2025 vs Dec 31, 2024) | Metric (Thousands USD) | June 30, 2025 | Dec 31, 2024 | Change | | :-------------------- | :------------ | :----------- | :----- | | Cash and cash equivalents | $4,402 | $6,260 | -29.7% | | Accounts receivable, net | $1,633 | $430 | +279.8% | | Total current assets | $6,730 | $7,473 | -9.9% | | Goodwill | $8,450 | $2,843 | +197.2% | | Property and equipment, net | $5,129 | $3,350 | +53.1% | | Intangible assets, net | $2,225 | $370 | +501.4% | | **Total assets** | **$26,033** | **$15,284** | **+70.3%** | | Accounts payable | $1,763 | $1,098 | +60.6% | | Total current liabilities | $6,426 | $4,978 | +29.1% | | Employee retention credit liability | $2,904 | $1,220 | +138.0% | | Debt, net of current portion | $7,760 | $0 | N/A | | **Total liabilities** | **$21,450** | **$7,330** | **+192.6%** | | **Total stockholders' equity** | **$4,583** | **$7,954** | **-42.4%** | [Company Information](index=3&type=section&id=Company%20Information) Vivos Therapeutics is a medical technology company focused on innovative diagnostic and treatment methods for Obstructive Sleep Apnea (OSA) using FDA-cleared CARE devices [About Vivos Therapeutics, Inc.](index=3&type=section&id=About%20Vivos%20Therapeutics%2C%20Inc.) Vivos Therapeutics is a medical technology company specializing in innovative diagnostic and treatment methods for breathing and sleep issues, particularly Obstructive Sleep Apnea (OSA) - Vivos Therapeutics (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing diagnostic and treatment methods for breathing and sleep issues, including Obstructive Sleep Apnea (OSA) and snoring[11](index=11&type=chunk) - Vivos' CARE devices are FDA 510(k) cleared for all severity levels of OSA in adults and moderate-to-severe OSA in children (ages 6-17), being the only technology cleared for **severe OSA in adults** and the first for children[11](index=11&type=chunk) - OSA affects over **1 billion people worldwide**, with **90% remaining undiagnosed**, and is closely linked to many serious chronic health conditions[12](index=12&type=chunk) - The Vivos Method offers a proprietary, clinically effective solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to Breathe New Life[14](index=14&type=chunk) - Founded in 2016 and based in Littleton, CO, Vivos aims to empower healthcare providers through innovative technology, education, and acquisitions of, or commercial collaborations with, sleep healthcare providers[13](index=13&type=chunk) [Additional Information](index=3&type=section&id=Additional%20Information) This section provides details on the Q2 2025 investor conference call and a cautionary note regarding forward-looking statements and associated risks [Investor Conference Call and 10-Q Filing](index=3&type=section&id=Investor%20Conference%20Call%20and%2010-Q%20Filing) Vivos Therapeutics hosted an investor conference call on August 19, 2025, to discuss Q2 2025 financial results, strategic collaborations, and their anticipated impact on revenue growth and cash burn - Vivos hosted an investor conference call on August 19, 2025, at 5:00 p.m. ET to discuss Q2 2025 results, strategic collaborations, and their effect on near-term revenue growth and cash burn[8](index=8&type=chunk) - Details for accessing the live call, replay, and webcast are provided, with the replay available until September 2, 2025[9](index=9&type=chunk) - Further financial information is included in the attached unaudited condensed consolidated balance sheets and statements of operations, and the full Quarterly Report on Form 10-Q will be filed with the SEC[10](index=10&type=chunk) [Cautionary Note Regarding Forward-Looking Statements](index=4&type=section&id=Cautionary%20Note%20Regarding%20Forward-Looking%20Statements) This section highlights that the press release contains forward-looking statements regarding the future impact of the SCN acquisition and the benefits of Vivos' new marketing model, warning of potential material differences in actual results - The press release contains forward-looking statements concerning future events, including the actual future impact of the SCN acquisition on Vivos' future revenues and results of operations and the anticipated benefits and potential expansion of Vivos' marketing and distribution model[16](index=16&type=chunk) - These statements involve significant known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos' control[16](index=16&type=chunk) - Factors that could cause actual results to differ materially include the risk that Vivos may be unable to successfully integrate SCN's business, the risk that some patients may not achieve desired results, risks associated with regulatory scrutiny, and the risk that Vivos may be unable to secure additional financing[16](index=16&type=chunk) - Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements, except to the extent required by law[16](index=16&type=chunk)

Financial Data and Key Metrics Changes - In Q2 2025, revenue decreased by approximately 6% to $3.8 million compared to $4.1 million in 2024, reflecting additional expenses related to the transition and integration of the Sleep Center of Nevada (SCN) [8][10] - Operating loss widened to $4.9 million in Q2 and $8.8 million for 2025, primarily due to higher expenses and lower revenues during the strategic transition [11][12] - Cash and cash equivalents stood at $4.4 million with total liabilities of $21.5 million as of June 30, 2025 [12] Business Line Data and Key Metrics Changes - VIP enrollment revenue declined by $1 million in Q2, while sleep testing service revenue saw an uplift of $500,000 attributable to SCN [9][10] - Oral appliance sales decreased by 5% in Q2, with 4,116 units sold for $1.9 million, reflecting a shift towards higher volume guide sales [10][11] Market Data and Key Metrics Changes - The integration of SCN has led to increased patient demand, with the company currently servicing significantly less than 40% of potential new patients being tested each month at SCN [18][19] - The company has identified a significant number of legacy SCN patients dissatisfied with CPAP units, indicating a strong market opportunity for VIVOS's treatment alternatives [18] Company Strategy and Development Direction - The company is focusing on a new sales, marketing, and distribution model centered around sleep center provider alliances and acquisitions, with the SCN acquisition being a key milestone [6][12] - VIVOS plans to expand its operations by deploying additional Sleep Optimization (SO) teams to meet growing patient demand, with potential for up to eight teams at SCN based on current demand [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the integration of SCN and the initial patient demand exceeding expectations, leading to plans for facility expansion and additional staff recruitment [14][18] - The company anticipates becoming cash flow positive by the fourth quarter of 2025 as it ramps up the deployment of SO teams [49] Other Important Information - The company has secured significant debt and equity financing, providing $11.5 million in net cash from financing activities [11][12] - VIVOS is actively pursuing additional acquisition and affiliation opportunities across the country, with ongoing negotiations with several potential candidates [22][39] Q&A Session Summary Question: How should revenue in Q3 and Q4 be viewed relative to Q2? - Management indicated that revenue will track the deployment of SO teams, with expectations for growth as the new model replaces the old one [26][27] Question: Will the strength in sleep testing services continue? - Management noted that the increase in testing revenue is a direct reflection of SCN's operations and expects continued growth as more testing centers are brought online [28][29] Question: What is the expected operating expense moving forward? - Management acknowledged that there were one-time costs associated with the SCN acquisition, but some ongoing costs will remain [31][32] Question: How is the recruitment of SO teams progressing? - Management reported robust demand for positions and efficient training processes for new teams [35][36] Question: What is the financial strategy regarding debt? - Management is focused on reducing the cost of capital and is exploring opportunities for refinancing as the business model matures [44][45] Question: When does management expect to reach cash breakeven? - Management is targeting cash flow positivity by the fourth quarter of 2025 as they expand operations [49]